Novo Nordisk loses another patent behind Ozempic and Wegovy drugs
Six years’ more or less market exclusivity makes a huge difference to originator manufacturers of blockbuster medicines. And, of course, to generic drug companies too. Consequently, the decision by EPO Board of Appeal 3.3.04 on Thursday afternoon is likely to have far-reaching consequences.